SP0090 INTENSIVE SMOKING CESSATION INTERVENTION
Authors: Ida Kristiane Roelsgaard
Journal: Annals of the Rheumatic Diseases (2019)

<h3></h3> Smokers with an inflammatory joint disease (IJD) experience poorer health-related quality of life compared to non-smokers with IJD (1). Smoking may exacerbate the symptoms of the disease and cause a reduced response to antirheumatic treatment (2-4). Smoking cessation interventions have traditionally been designed for people without chronic diseases (5). The literature on smoking cessation interventions to people with IJDs is limited. Initially, this lecture will focus on "state of the art" regarding smoking cessation interventions to people with IJD. Firstly, results from a systematic review will be presented. Randomised controlled trials (RCT) were included if they tested any form of smoking cessation intervention for adult daily smokers diagnosed with an IJD (6). Secondly, the lecture will focus on various interventions for smoking cessation e.g. brief advice, behavioural interventions, motivational interviewing and nicotine replacement therapy. Finally, principles for an ongoing RCTs where daily smokers with rheumatoid arthritis (RA) are randomised to either an intervention group or to a control group will be presented (7). The intervention consists of motivational counselling combined with nicotine replacement therapy. One patient research partner with RA (former smoker) has been involved with all phases of the study. The above indicate that smoking cessation may positively impact not only clinical outcomes but also patient reported outcomes. However, a limited number of studies on smoking cessation interventions and the effect of smoking cessation on clinical and patient reported outcomes to people with IJD have been published. The knowledge is therefore limited, and health professionals should focus on this subject to proactively support people with IJDs who wish to quit smoking. <h3>References:</h3> [1] Bremander A, Jacobsson LT, Bergman S, Haglund E, Lofvendahl S, Petersson IF. Smoking is associated with a worse self-reported health status in patients with psoriatic arthritis: data from a Swedish population-based cohort. Clinical rheumatology. 2015;34(3):579-83. [2] Chang K, Yang SM, Kim SH, Han KH, Park SJ, Shin JI. Smoking and rheumatoid arthritis. International journal of molecular sciences. 2014;15(12):22279-95. [3] Abhishek A, Butt S, Gadsby K, Zhang W, Deighton CM. Anti-TNF-alpha agents are less effective for the treatment of rheumatoid arthritis in current smokers. Journal of clinical rheumatology : practical reports on rheumatic &amp; musculoskeletal diseases. 2010;16(1):15-8. [4] Soderlin MK, Petersson IF, Geborek P. The effect of smoking on response and drug survival in rheumatoid arthritis patients treated with their first anti-TNF drug. Scandinavian journal of rheumatology. 2012;41(1):1-9. [5] Gritz ER, Vidrine DJ, Fingeret MC. Smoking cessation a critical component of medical management in chronic disease populations. American journal of preventive medicine. 2007;33(6 Suppl):S414-22. [6] Roelsgaard IK, Esbensen BA, Østergaard M, Rollefstad S, Semb AG, Christensen R, et al. Smoking cessation intervention for reducing disease activity in chronic autoimmune inflammatory joint diseases. Cochrane Database of Systematic Reviews. 2018(2). [7] Roelsgaard IK, Thomsen T, Ostergaard M, Christensen R, Hetland ML, Jacobsen S, et al. The effect of an intensive smoking cessation intervention on disease activity in patients with rheumatoid arthritis: study protocol for a randomised controlled trial. Trials. 2017;18(1):570. <h3>Disclosure of Interests:</h3> None declared